Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02253030 · ClinicalTrials.gov registry record
OCT Angiography in Wet AMD
A clinical trial of Neovascular (Wet) Age-related Macular Degeneration (AMD), sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- 160
- Enrollment target
- 1
- Study location
NCT02253030: Recruiting study of Neovascular (Wet) Age-related Macular Degeneration (AMD), sponsored by Oregon Health and Science University.
NCT02253030 is a study of Neovascular (Wet) Age-related Macular Degeneration (AMD) that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 160 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02253030, a study of Neovascular (Wet) Age-related Macular Degeneration (AMD), is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to: 1. diagnose the presence of new blood vessels in wet age-related macular degeneration (AMD) 2. evaluate patients undergoing treatment for wet AMD 3. determine if reduced flow to the choroid is a risk factor for developing wet AMD.
Conditions Studied
Interventions
- DEVICE Optical Coherence Tomography
Study Locations (1)
Oregon
- Casey Eye Institute, Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2014-09 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02253030
The ClinicalTrials.gov registry entry for NCT02253030 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neovascular (Wet) Age-related Macular Degeneration (AMD) appearing as the primary indexed condition, and to 1 intervention - of which Optical Coherence Tomography is the first listed.
NCT02253030 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT02253030 about?
NCT02253030 is a clinical study titled "OCT Angiography in Wet AMD". The primary goals of this study are to use optical coherence tomography (OCT) angiography (blood vessel mapping) to: 1. diagnose the presence of new blood vessels in wet age-related macular degeneration (AMD) 2. evaluate patients undergoing treatment for wet AMD 3. determine if reduced flow to the ...
What is the current status of trial NCT02253030?
This trial is currently recruiting. The enrollment target is 160 participants. The study started on 2014-09. Estimated completion is 2026-12.
What conditions does trial NCT02253030 study?
This clinical trial studies the following conditions: Neovascular (Wet) Age-related Macular Degeneration (AMD).
What interventions are being tested in trial NCT02253030?
The interventions under investigation include: Optical Coherence Tomography (DEVICE).
Who is sponsoring clinical trial NCT02253030?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02253030 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.